Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$2.70 -3.2%	$2.66	$2.12 ▼ $5.80	$268.19M	2.02	1.50 million shs	753,836 shs
ARCT Arcturus Therapeutics	$12.63 -0.8%	$11.30	$8.04 ▼ $45.00	$342.54M	2.36	446,967 shs	1.00 million shs
IOBT IO Biotech	$1.38 +14.0%	$1.01	$0.66 ▼ $1.73	$90.92M	0.09	275,871 shs	492,968 shs
SLDB Solid Biosciences	$3.20 -3.0%	$3.12	$2.41 ▼ $10.37	$248.05M	2.32	1.08 million shs	868,844 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	0.00%	+14.89%	-10.00%	+1.89%	-6.25%
ARCT Arcturus Therapeutics	0.00%	+3.52%	-1.56%	-19.45%	-67.46%
IOBT IO Biotech	0.00%	+14.05%	+35.29%	+59.85%	+16.95%
SLDB Solid Biosciences	0.00%	+13.88%	-25.75%	-37.50%	-61.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AQST Aquestive Therapeutics	1.2207 of 5 stars	3.5	1.0	2.3	0.0	0.0
ARCT Arcturus Therapeutics	2.8542 of 5 stars	4.6	0.0	2.6	2.5	0.6
IOBT IO Biotech	3.0357 of 5 stars	3.7	3.0	3.3	0.8	1.3
SLDB Solid Biosciences	3.921 of 5 stars	4.6	1.0	2.9	4.2	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQST Aquestive Therapeutics	3.00	Buy	$10.67	295.06% Upside
ARCT Arcturus Therapeutics	3.11	Buy	$53.50	323.59% Upside
IOBT IO Biotech	3.33	Buy	$9.33	576.33% Upside
SLDB Solid Biosciences	3.23	Buy	$14.90	365.63% Upside

Current Analyst Ratings Breakdown

Latest IOBT, ARCT, AQST, and SLDB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00
5/22/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$16.00
5/19/2025	SLDB Solid Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
5/16/2025	SLDB Solid Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$20.00 ➝ $17.00
5/16/2025	SLDB Solid Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$15.00 ➝ $10.00
5/16/2025	SLDB Solid Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$18.00 ➝ $17.00
5/15/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/14/2025	IOBT IO Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/14/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00
5/13/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/13/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $66.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQST Aquestive Therapeutics	$54.23M	4.95	N/A	N/A	($1.59) per share	-1.70
ARCT Arcturus Therapeutics	$131.27M	2.61	N/A	N/A	$10.42 per share	1.21
IOBT IO Biotech	N/A	N/A	N/A	N/A	$2.02 per share	N/A
SLDB Solid Biosciences	$8.09M	30.66	N/A	N/A	$6.27 per share	0.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQST Aquestive Therapeutics	-$7.87M	-$0.59	N/A	N/A	N/A	-59.75%	N/A	-33.96%	8/5/2025 (Estimated)
ARCT Arcturus Therapeutics	-$29.73M	-$2.53	N/A	N/A	N/A	-36.39%	-22.39%	-14.81%	8/4/2025 (Estimated)
IOBT IO Biotech	-$86.08M	-$1.37	N/A	N/A	N/A	N/A	-86.56%	-75.24%	8/12/2025 (Estimated)
SLDB Solid Biosciences	-$96.01M	-$2.99	N/A	N/A	N/A	N/A	-58.75%	-47.84%	8/12/2025 (Estimated)

Latest IOBT, ARCT, AQST, and SLDB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	SLDB Solid Biosciences	-$0.53	-$0.59	-$0.06	-$0.59	N/A	N/A
5/12/2025	Q1 2025	AQST Aquestive Therapeutics	-$0.17	-$0.24	-$0.07	-$0.24	$12.23 million	$8.72 million
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million
3/6/2025	Q4 2024	ARCT Arcturus Therapeutics	-$0.33	-$1.11	-$0.78	-$1.11	$44.64 million	$22.77 million
3/5/2025	Q4 2024	AQST Aquestive Therapeutics	-$0.14	-$0.19	-$0.05	-$0.19	$13.11 million	$11.87 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	$0.71	5.66%	N/A	N/A	N/A
IOBT IO Biotech	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQST Aquestive Therapeutics	N/A	6.37	5.91
ARCT Arcturus Therapeutics	N/A	4.76	4.76
IOBT IO Biotech	N/A	5.37	5.37
SLDB Solid Biosciences	N/A	7.85	7.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQST Aquestive Therapeutics	32.45%
ARCT Arcturus Therapeutics	94.54%
IOBT IO Biotech	54.76%
SLDB Solid Biosciences	81.46%

Insider Ownership

Company	Insider Ownership
AQST Aquestive Therapeutics	8.35%
ARCT Arcturus Therapeutics	16.60%
IOBT IO Biotech	4.80%
SLDB Solid Biosciences	13.63%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQST Aquestive Therapeutics	160	99.33 million	84.02 million	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.94 million	Optionable
IOBT IO Biotech	30	65.88 million	64.37 million	Not Optionable
SLDB Solid Biosciences	100	77.52 million	35.05 million	Optionable

IOBT, ARCT, AQST, and SLDB Headlines

Recent News About These Companies

Millennium Management LLC Sells 397,321 Shares of Solid Biosciences Inc. (NASDAQ:SLDB)

June 1 at 3:43 AM | marketbeat.com

Solid Biosciences’ SWOT analysis: gene therapy stock poised for potential breakthrough

May 28, 2025 | investing.com

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

May 28, 2025 | globenewswire.com

Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Recommendation of "Buy" by Brokerages

May 28, 2025 | marketbeat.com

Research Analysts Set Expectations for SLDB FY2025 Earnings

May 27, 2025 | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Earns "Overweight" Rating from Cantor Fitzgerald

May 24, 2025 | marketbeat.com

Chardan Capital Has Lowered Expectations for Solid Biosciences (NASDAQ:SLDB) Stock Price

May 21, 2025 | marketbeat.com

Q1 Earnings Forecast for SLDB Issued By William Blair

May 21, 2025 | marketbeat.com

Truist maintains buy on Solid Biosciences stock, price target at $16

May 18, 2025 | investing.com

Dimensional Fund Advisors LP Purchases 192,714 Shares of Solid Biosciences Inc. (NASDAQ:SLDB)

May 18, 2025 | marketbeat.com

When Might Solid Biosciences Run Out Of Money?

May 17, 2025 | finance.yahoo.com

Solid Biosciences (NASDAQ:SLDB) Upgraded by Cantor Fitzgerald to "Strong-Buy" Rating

May 17, 2025 | marketbeat.com

Solid Biosciences Inc.: Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

May 16, 2025 | finanznachrichten.de

Solid Biosciences (SLDB) Expected to Announce Earnings on Wednesday

May 16, 2025 | marketbeat.com

Solid Biosciences files for $400M mixed securities shelf offering

May 16, 2025 | msn.com

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

May 15, 2025 | globenewswire.com

Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Rating of "Buy" by Brokerages

May 4, 2025 | marketbeat.com

Why Solid Biosciences Inc.’s (SLDB) Stock Is Up 10.82%

May 3, 2025 | aaii.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2025 | globenewswire.com

Solid Biosciences to Present Phase 1/2 Trial Data for SGT-003 Gene Therapy at ASGCT 2025 Annual Meeting

May 1, 2025 | nasdaq.com

Solid Biosciences to Participate at The Citizens Life Sciences Conference

April 30, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOBT, ARCT, AQST, and SLDB Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

$2.70 -0.09 (-3.23%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$2.71 +0.01 (+0.37%)

As of 03:59 AM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Arcturus Therapeutics NASDAQ:ARCT

$12.63 -0.10 (-0.79%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$12.53 -0.10 (-0.79%)

As of 04:01 AM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

IO Biotech NASDAQ:IOBT

$1.38 +0.17 (+14.05%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.42 +0.04 (+2.90%)

As of 04:00 AM Eastern

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Solid Biosciences NASDAQ:SLDB

$3.20 -0.10 (-3.03%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$3.21 +0.01 (+0.31%)

As of 03:59 AM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time